Abstract

Chronic rhinosinusitis (CRS) is widely prevalent within the population and often leads to decreased quality of life, among other related health complications. CRS has classically been stratified by the presence of nasal polyps (CRSwNP) or the absence nasal polyps (CRSsNP). Management of these conditions remains a challenge as investigators continue to uncover potential etiologies and therapeutic targets. Recently, attention has been given to the sinunasal microbiota as both an inciting and protective influence of CRS development. The healthy sinunasal microbiologic environment is largely composed of bacteria, with the most frequent strains including Staphylococcus aureus, Streptococcus epidermidis, and Corynebacterium genera. Disruptions in this milieu, particularly increases in S. aureus concentration, have been hypothesized to perpetuate both Th1 and Th2 inflammatory changes within the nasal mucosa, leading to CRS exacerbation and potential polyp formation. Other contributors to the sinunasal microbiota include fungi, viruses, and bacteriophages which may directly contribute to underlying inflammation or impact bacterial prevalence. Modifiable risk factors, such as smoking, have also been linked to microbiota alterations. Research interest in CRS continues to expand, and thus the goal of this review is to provide clinicians and investigators alike with a current discussion on the microbiologic influence on CRS development, particularly with respect to the expression of various phenotypes. Although this subject is rapidly evolving, a greater understanding of these potential factors may lead to novel research and targeted therapies for this often difficult to treat condition.

Highlights

  • The human microbiota plays a crucial role in the preservation of human health, and investigations into this complex ecosystem have become a key focus in medical research [1]

  • The most common bacteria were proportionally similar across Chronic rhinosinusitis (CRS) cohorts in these culture-dependent investigations, stratification by blood eosinophil level and asthma identified potential associations with CRS with nasal polyps (CRSwNP) and certain pathogens, S. aureus and S. epidermidis

  • Evidence suggests that certain probiotic strains have the potential to have immunomodulatory effects that favor the stimulation of a Th1 profile, further augmenting humoral immunity with increases in IgA production and enhanced mucosal defense immune responses [75]. Another potential method to modify disease risk by further altering the nasal microbiome is the use of intranasal corticosteroids; the use of intranasal corticosteroids has been shown to modify the commensal microbiota and may further serve to decrease the density of pathogenic strains of colonizing bacteria related to the development of CRS [76]

Read more

Summary

Frontiers in Allergy

Research interest in CRS continues to expand, and the goal of this review is to provide clinicians and investigators alike with a current discussion on the microbiologic influence on CRS development, with respect to the expression of various phenotypes. This subject is rapidly evolving, a greater understanding of these potential factors may lead to novel research and targeted therapies for this often difficult to treat condition

INTRODUCTION
Pathogenesis of CRS With and Without Nasal Polyps
Classifying the Healthy Nasal Cavity Microbiota
COMPARING THE MICROBIOTAS OF CRSWNP AND CRSSNP
CRSwNP CRSsNP Allergic Rhinitis
Microbiota of Allergic Rhinitis
Role of the Nasopharyngeal Microbiome in CRS and Polyp Development
Modifying Disease Risk
LIMITATIONS
CONCLUSIONS
Findings
AUTHOR CONTRIBUTIONS
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call